2 assets in Inflammatory Myofibroblastic Tumor

Therapeutic assets addressing Inflammatory Myofibroblastic Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Crizotinib Inflammatory Myofibroblastic Tumor	Pfizer	P4	BB (69)
Brigatinib Inflammatory Myofibroblastic Tumor	Princess Maxima Center for Pediatric Oncology	P1/2	CCC (48)